claim: relief therapeutics and neurorx meet 165 patient enrollment target in phase 2b/3 trial of rlf-100 for critical covid-19 with respiratory failure
evidence_1: rlf-100 is being investigated in two placebo-controlled us phase 2b/3 clinical trials in respiratory deficiency due to covid-19.", "while the companies have focused first on those patients who have no medical alternative and are at immediate risk of death, a phase 2b/3 trial with rlf-100 for inhaled use in patients with moderate and severe covid-19 in order to prevent progression to respiratory failure is expected to start soon.")